Literature DB >> 1330170

Non-specific activity of (+/-)-CP-96,345 in models of pain and inflammation.

A Nagahisa1, R Asai, Y Kanai, A Murase, M Tsuchiya-Nakagaki, T Nakagaki, T C Shieh, K Taniguchi.   

Abstract

The non-peptide NK1 receptor antagonist, CP-96,345, and its 2R,3R enantiomer CP-96,344, which is not an NK1 receptor antagonist (IC50 > 10 microM), were evaluated for antinociceptive and anti-inflammatory activities in several classical models of pain and inflammation in the rat. Both CP-96,345 and CP-96,344 reduced carrageenin-induced paw oedema and hyperalgesia, and attenuated the second phase of formalin-induced paw licking with equal potency. These results indicate that NK1 antagonism is not responsible for the activity of (+/-)-CP-96,345 in the above animal models.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1330170      PMCID： PMC1907865          DOI： 10.1111/j.1476-5381.1992.tb12737.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  8 in total

1.  The non-peptide tachykinin antagonist, CP-96,345, is a potent inhibitor of neurogenic inflammation.

Authors:  F Lembeck; J Donnerer; M Tsuchiya; A Nagahisa
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

2.  Inhibition of tachykinin-induced hypotension in dogs by CP-96,345, a selective blocker of NK-1 receptors.

Authors:  J W Constantine; W S Lebel; H A Woody
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

3.  Role of NK1 tachykinin receptors in thermonociception: effect of (+/-)-CP 96,345, a non-peptide substance P antagonist, on the hot plate test in mice.

Authors:  A Lecci; S Giuliani; R Patacchini; G Viti; C A Maggi
Journal:  Neurosci Lett       Date:  1991-08-19       Impact factor: 3.046

4.  The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats.

Authors:  David Dubuisson; Stephen G Dennis
Journal:  Pain       Date:  1977-12       Impact factor: 6.961

5.  A potent nonpeptide antagonist of the substance P (NK1) receptor.

Authors:  R M Snider; J W Constantine; J A Lowe; K P Longo; W S Lebel; H A Woody; S E Drozda; M C Desai; F J Vinick; R W Spencer
Journal:  Science       Date:  1991-01-25       Impact factor: 47.728

6.  Antiinflammatory and analgesic activity of a non-peptide substance P receptor antagonist.

Authors:  A Nagahisa; Y Kanai; O Suga; K Taniguchi; M Tsuchiya; J A Lowe; H J Hess
Journal:  Eur J Pharmacol       Date:  1992-07-07       Impact factor: 4.432

7.  The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1- azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonisst.

Authors:  J A Lowe; S E Drozda; R M Snider; K P Longo; S H Zorn; J Morrone; E R Jackson; S McLean; D K Bryce; J Bordner
Journal:  J Med Chem       Date:  1992-07-10       Impact factor: 7.446

8.  The non-peptide NK1 receptor antagonist, (+/-)-CP-96,345, produces antinociceptive and anti-oedema effects in the rat.

Authors:  P J Birch; S M Harrison; A G Hayes; H Rogers; M B Tyers
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739
  8 in total
  8 in total

1.  Investigation of the specificity of FK 888 as a tachykinin NK1 receptor antagonist.

Authors:  Z Y Wang; S R Tung; G R Strichartz; R Håkanson
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

2.  Non-specific actions of the non-peptide tachykinin receptor antagonists, CP-96,345, RP 67580 and SR 48968, on neurotransmission.

Authors:  Z Y Wang; S R Tung; G R Strichartz; R Håkanson
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

3.  Antinociceptive activity of NK1 receptor antagonists: non-specific effects of racemic RP67580.

Authors:  N M Rupniak; S Boyce; A R Williams; G Cook; J Longmore; G R Seabrook; M Caeser; S D Iversen; R G Hill
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

4.  Block of voltage-dependent sodium currents by the substance P receptor antagonist (+/-)-CP-96,345 in neurones cultured from rat cortex.

Authors:  M Caeser; G R Seabrook; J A Kemp
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

5.  An isobolographic analysis of the effects of N-methyl-D-aspartate and NK1 tachykinin receptor antagonists on inflammatory hyperalgesia in the rat.

Authors:  K Ren; M J Iadarola; R Dubner
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

6.  The interaction of the NK1 receptor antagonist CP-96,345 with L-type calcium channels and its functional consequences.

Authors:  S Guard; S J Boyle; K W Tang; K J Watling; A T McKnight; G N Woodruff
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

7.  Effect of RP 67580, a non-peptide neurokinin1 receptor antagonist, on facilitation of a nociceptive spinal flexion reflex in the rat.

Authors:  J M Laird; R J Hargreaves; R G Hill
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

8.  Antinociceptive activity of the tachykinin NK1 receptor antagonist, CP-99,994, in conscious gerbils.

Authors:  N M Rupniak; J K Webb; A R Williams; E Carlson; S Boyce; R G Hill
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.